Development of an inactivated vaccine candidate for SARS-CoV-2

Science. 2020 Jul 3;369(6499):77-81. doi: 10.1126/science.abc1932. Epub 2020 May 6.

Abstract

The coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has resulted in an unprecedented public health crisis. Because of the novelty of the virus, there are currently no SARS-CoV-2-specific treatments or vaccines available. Therefore, rapid development of effective vaccines against SARS-CoV-2 are urgently needed. Here, we developed a pilot-scale production of PiCoVacc, a purified inactivated SARS-CoV-2 virus vaccine candidate, which induced SARS-CoV-2-specific neutralizing antibodies in mice, rats, and nonhuman primates. These antibodies neutralized 10 representative SARS-CoV-2 strains, suggesting a possible broader neutralizing ability against other strains. Three immunizations using two different doses, 3 or 6 micrograms per dose, provided partial or complete protection in macaques against SARS-CoV-2 challenge, respectively, without observable antibody-dependent enhancement of infection. These data support the clinical development and testing of PiCoVacc for use in humans.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antibodies, Neutralizing / biosynthesis
  • Antibodies, Neutralizing / blood*
  • Antibodies, Neutralizing / immunology
  • Antibodies, Viral / biosynthesis
  • Antibodies, Viral / blood*
  • Antibodies, Viral / immunology
  • Betacoronavirus / immunology*
  • Betacoronavirus / isolation & purification
  • Chlorocebus aethiops
  • Coronavirus Infections / immunology
  • Coronavirus Infections / prevention & control*
  • Coronavirus Infections / virology
  • Dose-Response Relationship, Immunologic
  • Female
  • Immunogenicity, Vaccine
  • Immunoglobulin G / biosynthesis
  • Immunoglobulin G / blood
  • Immunoglobulin G / immunology
  • Macaca mulatta
  • Male
  • Mice
  • Mice, Inbred BALB C
  • Pandemics / prevention & control*
  • Pilot Projects
  • Pneumonia, Viral / prevention & control*
  • Pneumonia, Viral / virology
  • Rats
  • Rats, Wistar
  • Vaccines, Inactivated / administration & dosage
  • Vaccines, Inactivated / adverse effects
  • Vaccines, Inactivated / immunology
  • Vero Cells
  • Viral Load
  • Viral Vaccines* / administration & dosage
  • Viral Vaccines* / adverse effects
  • Viral Vaccines* / immunology

Substances

  • Antibodies, Neutralizing
  • Antibodies, Viral
  • COVID-19 vaccine
  • Immunoglobulin G
  • Vaccines, Inactivated
  • Viral Vaccines

Supplementary concepts

  • COVID-19
  • severe acute respiratory syndrome coronavirus 2